Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 1
2016 1
2017 1
2018 2
2019 2
2020 2
2021 3
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
What is the best treatment strategy before autologous peripheral blood stem cell transplantation in POEMS syndrome?
Autore F, Bramanti S, Lessi F, Innocenti I, Galli E, Rocchi S, Ribolla R, Derudas D, Oliva S, Stefanoni P, Marcatti M, Schenone A, La Nasa G, Crippa C, Zamagni E, Riva M, Mazza R, Mannina D, Sica S, Bacigalupo A, Laurenti L. Autore F, et al. Among authors: ribolla r. Haematologica. 2024 Mar 1;109(3):888-894. doi: 10.3324/haematol.2023.283719. Haematologica. 2024. PMID: 37646655 Free PMC article.
Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study.
Lesokhin A, LeBlanc R, Dimopoulos MA, Capra M, Carlo-Stella C, Karlin L, Castilloux JF, Forsberg P, Parmar G, Tosikyan A, Pour L, Ribrag V, Ribolla R, Abdallah AO, Le Roux N, Dong L, van de Velde H, Mayrargue L, Lépine L, Macé S, Moreau P. Lesokhin A, et al. Among authors: ribolla r. Cancer Med. 2023 May;12(9):10254-10266. doi: 10.1002/cam4.5753. Epub 2023 Mar 3. Cancer Med. 2023. PMID: 36866838 Free PMC article. Clinical Trial.
Predictive role of diffusion-weighted whole-body MRI (DW-MRI) imaging response according to MY-RADS criteria after autologous stem cell transplantation in patients with multiple myeloma and combined evaluation with MRD assessment by flow cytometry.
Belotti A, Ribolla R, Cancelli V, Villanacci A, Angelini V, Chiarini M, Giustini V, Facchetti GV, Roccaro AM, Ferrari S, Peli A, Bottelli C, Cattaneo C, Crippa C, Micilotta M, Frittoli B, Grazioli L, Rossi G, Tucci A. Belotti A, et al. Among authors: ribolla r. Cancer Med. 2021 Sep;10(17):5859-5865. doi: 10.1002/cam4.4136. Epub 2021 Jul 15. Cancer Med. 2021. PMID: 34263564 Free PMC article.
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial.
Oliva S, Bruinink DHO, Rihova L, D'Agostino M, Pantani L, Capra A, van der Holt B, Troia R, Petrucci MT, Villanova T, Vsianska P, Jugooa R, Brandt-Hagens C, Gilestro M, Offidani M, Ribolla R, Galli M, Hajek R, Gay F, Cavo M, Omedé P, van der Velden VHJ, Boccadoro M, Sonneveld P. Oliva S, et al. Among authors: ribolla r. Blood Cancer J. 2021 Jun 3;11(6):106. doi: 10.1038/s41408-021-00498-0. Blood Cancer J. 2021. PMID: 34083504 Free PMC article. Clinical Trial.
Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity.
Sacco A, Federico C, Todoerti K, Ziccheddu B, Palermo V, Giacomini A, Ravelli C, Maccarinelli F, Bianchi G, Belotti A, Ribolla R, Favasuli V, Revenko AS, Macleod AR, Willis B, Cai H, Hauser J, Rooney C, Willis SE, Martin PL, Staniszewska A, Ambrose H, Hanson L, Cattaneo C, Tucci A, Rossi G, Ronca R, Neri A, Mitola S, Bolli N, Presta M, Moschetta M, Ross S, Roccaro AM. Sacco A, et al. Among authors: ribolla r. Blood. 2021 Nov 4;138(18):1705-1720. doi: 10.1182/blood.2020010572. Blood. 2021. PMID: 34077955 Free PMC article.
Transplant eligibility in elderly multiple myeloma patients: Prospective external validation of the international myeloma working group frailty score and comparison with clinical judgment and other comorbidity scores in unselected patients aged 65-75 years.
Belotti A, Ribolla R, Cancelli V, Crippa C, Bianchetti N, Ferrari S, Bottelli C, Cattaneo C, Tucci A, De La Fuente Barrigon C, Rossi G. Belotti A, et al. Among authors: ribolla r. Am J Hematol. 2020 Jul;95(7):759-765. doi: 10.1002/ajh.25797. Epub 2020 Apr 23. Am J Hematol. 2020. PMID: 32242970 Free article. Clinical Trial.
Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs.
Montefusco V, Gay F, Spada S, De Paoli L, Di Raimondo F, Ribolla R, Musolino C, Patriarca F, Musto P, Galieni P, Ballanti S, Nozzoli C, Cascavilla N, Ben-Yehuda D, Nagler A, Hajek R, Offidani M, Liberati AM, Sonneveld P, Cavo M, Corradini P, Boccadoro M. Montefusco V, et al. Among authors: ribolla r. Haematologica. 2020 Jan;105(1):193-200. doi: 10.3324/haematol.2019.219139. Epub 2019 Jun 20. Haematologica. 2020. PMID: 31221778 Free PMC article.
Circulating microRNAs and Their Role in Multiple Myeloma.
Federico C, Sacco A, Belotti A, Ribolla R, Cancelli V, Giacomini A, Ronca R, Chiarini M, Imberti L, Marini M, Rossi G, Presta M, Paiva B, Roccaro AM. Federico C, et al. Among authors: ribolla r. Noncoding RNA. 2019 May 2;5(2):37. doi: 10.3390/ncrna5020037. Noncoding RNA. 2019. PMID: 31052608 Free PMC article. Review.
Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials.
D'Agostino M, De Paoli L, Conticello C, Offidani M, Ria R, Petrucci MT, Spada S, Marcatti M, Catalano L, Gilestro M, Guglielmelli T, Baldini L, Gamberi B, Rizzi R, De Sabbata G, Di Renzo N, Patriarca F, Pezzatti S, Siniscalchi A, Ribolla R, Palumbo A, Montefusco V, Nagler A, Boccadoro M, Gay F. D'Agostino M, et al. Among authors: ribolla r. Crit Rev Oncol Hematol. 2018 Dec;132:9-16. doi: 10.1016/j.critrevonc.2018.09.008. Epub 2018 Sep 14. Crit Rev Oncol Hematol. 2018. PMID: 30447931 Free article. Review.
14 results